NCT01248468View on ClinicalTrials.gov

Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine

PHASE4CompletedINTERVENTIONAL

Enrollment

752

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Pain, Migraine

Interventions

DRUG

Aspirin, acetaminophen and caffeine

2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)

DRUG

Sumatriptan

100 mg Sumatriptan

DRUG

Placebo

placebo

Trial Locations (20)

Unknown

Anaheim

San Francisco

Clearwater

DeLand

Jacksonville

Miami

Pembroke Pines

West Palm Beach

Chicago

Ann Arbor

Springfield

Rochester

The Bronx

Raleigh

Cleveland

Mt. Pleasant

Nashville

San Antonio

Salt Lake City

Seattle

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Novartis

INDUSTRY

NCT01248468 - Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine | Biotech Hunter | Biotech Hunter